Sudoscan and Withings Participation at the 20th Malvern Diabetic Foot Conference from Wednesday 15 to Friday 17 may 2024

Aurora BioScience is a Distribution partner for SUDOSCAN in Australia & New Zealand

SUDOSCAN enables healthcare professionals to access advanced solutions for neuropathy and sudomotor dysfunction diagnosis in just 3 minutes.

The Malvern Diabetic Foot Conference gathers various healthcare experts, including physicians, surgeons, podiatrists, orthopedists, and nursing staff, from over 30 countries.

Sudoscan and Withings will be participating in this prestigious conference. Sudoscan has the potential to significantly improve outcomes for patients with diabetes. We will showcase the effectiveness and innovation of our unique technology that helps manage diabetic foot issues by identifying neuropathy.

Spotlight on the 2024 Malvern Diabetic Foot Conference

The Malvern Diabetic Foot Conference is celebrating its 20th edition. Originating in 1986, this event gathers medical professionals from diverse fields, for three days of learning and discussion. In addition to opportunities of learning the latest trends in diabetic foot management, the conference also offers a unique occasion for professionals to connect and engage with each other.

The conference will cover a range of topics related to diabetic foot care, including but not limited to:

• Prevention and management of diabetic foot ulcers
• Advances in wound care for diabetic patients
• Surgical interventions for diabetic foot complications
• Multidisciplinary approaches to diabetic foot care
• Technology and innovation in diabetic foot management

Click here for more about the conference.

Advance in Diabetic Foot Care: Sudoscan’s Promising Technology

Sudoscan is a fast, easy-to-use, and safe non-invasive tool, which provides standardized skin conductance measurements within three minutes. The Sudoscan device measures the ability of the sweat glands to release chloride ions in response to an electrical stimulus.

Sudoscan has been used in the management of various conditions including diabetes, Parkinson’s disease, and fibromyalgia. With CE and FDA certification, this technology offers reliable and consistent results with the unique benefit of an objective measurement of small nerve fiber function.

Considering these positive findings, health professionals are interested in learning more about Sudoscan and its potential uses in diabetic foot care. Further reinforcing Sudoscan’s efficacy, several studies over the past 23 years have evaluated the tool’s reproducibility and efficacy in detecting diabetic neuropathy (DN) :

• A study confirmed that Sudoscan can detect neuropathy in patients with DM, with a sensitivity of 78% and a specificity of 92%, equivalent to or better than clinical neuropathy scores. Sudoscan results correlate significantly with clinical measures of neuropathy, somatic and autonomic function testing, and pain scores. Feet ESC was significantly decreased in patients with painful DN compared with the value in patients with nonpainful neuropathy. Test–retest reliability is excellent for the feet. (Source : Sudoscan, a Noninvasive Tool for Detecting Diabetic Small Fiber Neuropathy and Autonomic Dysfunction).
• In another study, Sudoscan proved to be a valuable tool, providing insightful data on sudomotor function. The results obtained from Sudoscan measurements significantly contributed to the analysis and findings of the research. Its non-invasive nature and ability to assess sweat gland activity efficiently made it an indispensable asset in the study. (Source : Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy).
• Additionally, another study confirmed the utility of Sudoscan in diabetic foot care by showing significantly higher feet asymmetry in diabetic foot patients compared to others. The test’s discriminative value and predictive power highlight its importance as an early marker for neuropathy evaluation. (Source : The role of Sudoscan feet asymmetry in the diabetic foot).

About Sudoscan and Withings

Withings, a leader in smart health devices, recently acquired Sudoscan, expanding their range of products. Established in 2008, Withings has transformed the health sector with its smart devices and apps. Its diverse range of clinically-approved products have benefitted millions of users globally.

The integration of Sudoscan technology into Withings’ ecosystem provides users with new abilities to manage their well-being. Sudoscan also benefits from Withings’ resources to offer more innovative technology to healthcare professionals in the field of diabetology.

Sudoscan’s attendance at the 2024 Malvern Diabetic Foot Conference aims to inspire health professionals to discover this cutting-edge technology, and to discuss its potential in the field of diabetology. This will be a great opportunity for valuable discussions and sharing of innovative discoveries.

Sudoscan and Withings will showcase Sudoscan’s unique solutions at the conference. Come see how our technology is changing the way to manage diabetic foot care!